Remedy Robotics Raises $62 million Series B to Support Clinical Trials and Planned Deployment

Remedy Robotics, Inc. raised $62 million in Series B funding led by DCVC, with participation from UC Investments, Skip Capital, Hostplus, Build Collective by Tony Fadell, Blackbird, Divergent Capital and KdT Ventures. The funding will support clinical trials, advancement toward FDA approval and planned commercial deployment of its AI-enabled endovascular robotic platform and software suite.
- Raised
- $62 million
- Round
- Series B
- Investors
- 8
- Investors
- DCVCUC InvestmentsSkip CapitalHostplusBuild Collective by Tony FadellBlackbirdDivergent CapitalKdT Ventures
- Target market
- Patients needing cardiovascular care and endovascular intervention
- Use of funds
- Supporting clinical trials, advancement toward FDA approval, and planned commercial deployment of the AI-enabled endovascular robotic platform and software suite
Get started
Create a free account to read the full story.
Quick Answers
What is the latest news about Remedy Robotics, Inc.?
Remedy Robotics, Inc. raised $62 million in Series B funding led by DCVC, with participation from UC Investments, Skip Capital, Hostplus, Build Collective by Tony Fadell, Blackbird, Divergent Capital and KdT Ventures. The funding will support clinical trials, advancement toward FDA approval and planned commercial deployment of its AI-enabled endovascular robotic platform and software suite.
What does Remedy Robotics, Inc. do?
Headquartered in San Francisco, Remedy Robotics develops AI-enabled endovascular robotic systems and software for on-premise, remote and autonomous intervention. Its clinical and research work has appeared in Interventional Neuroradiology and the American Journal of Neuroradiology.
How much did Remedy Robotics, Inc. raise?
Remedy Robotics, Inc. raised $62 million in its Series B.
Who invested in Remedy Robotics, Inc.?
Investors named in this Series B include DCVC, UC Investments, Skip Capital, Hostplus, Build Collective by Tony Fadell, Blackbird, Divergent Capital and KdT Ventures.
How will Remedy Robotics, Inc. use the funding?
Remedy Robotics, Inc. plans to use the money for supporting clinical trials, advancement toward FDA approval, and planned commercial deployment of the AI-enabled endovascular robotic platform and software suite.
Where is Remedy Robotics, Inc. based?
Remedy Robotics, Inc. is based in USA.
Who are the key people at Remedy Robotics, Inc.?
Key people named in this report: Dr. David Bell (CEO and Co-Founder) and Jake Sganga (Co-Founder and CTO).
